Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse

Authors: Thomas R Moench, Russell J Mumper, Timothy E Hoen, Mianmian Sun, Richard A Cone

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Several active ingredients proposed as vaginal microbicides have been shown paradoxically to increase susceptibility to infection in mouse genital herpes (HSV-2) vaginal susceptibility models and in clinical trials. In addition, "inactive ingredients" (or excipients) used in topical products to formulate and deliver the active ingredient might also cause epithelial toxicities that increase viral susceptibility. However, excipients have not previously been tested in susceptibility models.

Methods

Excipients commonly used in topical products were formulated in a non-toxic vehicle (the "HEC universal placebo"), or other formulations as specified. Twelve hours after exposure to the excipient or a control treatment, mice were challenged with a vaginal dose of HSV-2, and three days later were assessed for infection by vaginal lavage culture to assess susceptibility.

Results

The following excipients markedly increased susceptibility to HSV-2 after a single exposure: 5% glycerol monolaurate (GML) formulated in K-Y® Warming Jelly, 5% GML as a colloidal suspension in phosphate buffered saline, K-Y Warming Jelly alone, and both of its humectant/solvent ingredients (neat propylene glycol and neat PEG-8). For excipients formulated in the HEC vehicle, 30% glycerin significantly increased susceptibility, and a trend toward increased HSV-2 susceptibility was observed after 10% glycerin, and 0.1% disodium EDTA, but not after 0.0186% disodium EDTA. The following excipients did not increase susceptibility: 10% propylene glycol, 0.18%, methylparaben plus 0.02% propylparaben, and 1% benzyl alcohol.

Conclusions

As reported with other surfactants, the surfactant/emulsifier GML markedly increased susceptibility to HSV-2. Glycerin at 30% significantly increased susceptibility, and, undiluted propylene glycol and PEG-8 greatly increased susceptibility.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, et al: Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992, 268: 477-82. 10.1001/jama.268.4.477.CrossRefPubMed Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, et al: Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992, 268: 477-82. 10.1001/jama.268.4.477.CrossRefPubMed
2.
go back to reference Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M: COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002, 360 (9338): 971-7. 10.1016/S0140-6736(02)11079-8.CrossRefPubMed Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M: COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002, 360 (9338): 971-7. 10.1016/S0140-6736(02)11079-8.CrossRefPubMed
3.
go back to reference Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008, 3 (1): e1474.4-10.1371/journal.pone.0001474.CrossRef Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008, 3 (1): e1474.4-10.1371/journal.pone.0001474.CrossRef
4.
go back to reference Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D, CS Study Group: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008, 359: 463-72. 10.1056/NEJMoa0707957.CrossRefPubMed Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D, CS Study Group: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008, 359: 463-72. 10.1056/NEJMoa0707957.CrossRefPubMed
5.
go back to reference Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M: Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009, 9: 118-29. 10.1016/S1473-3099(09)70021-0.CrossRefPubMedPubMedCentral Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M: Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009, 9: 118-29. 10.1016/S1473-3099(09)70021-0.CrossRefPubMedPubMedCentral
6.
go back to reference Sodora DL, Gettie A, Miller CJ, Marx PA: Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses. 1998, 14 (Suppl 1): S119-123.PubMed Sodora DL, Gettie A, Miller CJ, Marx PA: Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses. 1998, 14 (Suppl 1): S119-123.PubMed
7.
go back to reference Bishop SA, Stokes CR, Gruffydd-Jones TJ, Whiting CV, Harbour DA: Vaginal and rectal infection of cats with feline immunodeficiency virus. Vet Microbiol. 1966, 51: 217-227. 10.1016/0378-1135(96)00038-7.CrossRef Bishop SA, Stokes CR, Gruffydd-Jones TJ, Whiting CV, Harbour DA: Vaginal and rectal infection of cats with feline immunodeficiency virus. Vet Microbiol. 1966, 51: 217-227. 10.1016/0378-1135(96)00038-7.CrossRef
8.
go back to reference Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis. 2001, 184 (4): 418-28. 10.1086/322047.CrossRefPubMed Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis. 2001, 184 (4): 418-28. 10.1086/322047.CrossRefPubMed
9.
go back to reference Doncel GF, Chandra N, Fichorova RN: Preclinical assessment of the proinflammatory potential of microbicide candidates. J Acquir Immune Defic Syndr. 2004, 37 (Suppl 3): S174-80.PubMed Doncel GF, Chandra N, Fichorova RN: Preclinical assessment of the proinflammatory potential of microbicide candidates. J Acquir Immune Defic Syndr. 2004, 37 (Suppl 3): S174-80.PubMed
10.
go back to reference Adriaens E, Remon JP: Evaluation of an alternative mucosal irritation test using slugs. Toxicol Appl Pharmacol. 2002, 182: 169-75. 10.1006/taap.2002.9444.CrossRefPubMed Adriaens E, Remon JP: Evaluation of an alternative mucosal irritation test using slugs. Toxicol Appl Pharmacol. 2002, 182: 169-75. 10.1006/taap.2002.9444.CrossRefPubMed
11.
go back to reference Adriaens E, Remon JP: Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis. 2008, 35: 512-6. 10.1097/OLQ.0b013e3181644669.CrossRefPubMed Adriaens E, Remon JP: Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis. 2008, 35: 512-6. 10.1097/OLQ.0b013e3181644669.CrossRefPubMed
12.
go back to reference Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR: Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis. 2006, 6: 90-10.1186/1471-2334-6-90.CrossRefPubMedPubMedCentral Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR: Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis. 2006, 6: 90-10.1186/1471-2334-6-90.CrossRefPubMedPubMedCentral
13.
go back to reference Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, Wilson SS, Porter DD, Lira SA, Keller MJ, Herold BC: A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis. 2007, 195: 1332-9. 10.1086/513279.CrossRefPubMed Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, Wilson SS, Porter DD, Lira SA, Keller MJ, Herold BC: A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis. 2007, 195: 1332-9. 10.1086/513279.CrossRefPubMed
14.
go back to reference Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Meller MJ, Herlod BC: Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infct Dis. 2009, 200: 599-608. 10.1086/600867. See also: Keller Marla. In vivo models of safety. Oral presentation, Microbicides 2008 Conference, 24-27 February 2008, Dehli, IndiaCrossRef Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Meller MJ, Herlod BC: Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infct Dis. 2009, 200: 599-608. 10.1086/600867. See also: Keller Marla. In vivo models of safety. Oral presentation, Microbicides 2008 Conference, 24-27 February 2008, Dehli, IndiaCrossRef
15.
go back to reference Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F: In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005, 39: 1-8. 10.1097/01.qai.0000159671.25950.74.CrossRefPubMed Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F: In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005, 39: 1-8. 10.1097/01.qai.0000159671.25950.74.CrossRefPubMed
16.
go back to reference Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, Doncel G, Watson K, Buckheit RW, Lewis MG, Schwartz J, Douville K, Romano JW: In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005, 21: 845-53. 10.1089/aid.2005.21.845.CrossRefPubMed Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, Doncel G, Watson K, Buckheit RW, Lewis MG, Schwartz J, Douville K, Romano JW: In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005, 21: 845-53. 10.1089/aid.2005.21.845.CrossRefPubMed
17.
go back to reference Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF, Callahan MM: Fourteen-day safety and acceptability study of the universal placebo gel. Contraception. 2007, 75: 136-41. 10.1016/j.contraception.2006.09.003.CrossRefPubMed Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF, Callahan MM: Fourteen-day safety and acceptability study of the universal placebo gel. Contraception. 2007, 75: 136-41. 10.1016/j.contraception.2006.09.003.CrossRefPubMed
18.
go back to reference Karim SA, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, Taha T, Kapina M, Maslankowski L, Soto-Tores L: Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PrO 2000/5 Gel for the prevention of HIV infection in women: results of the HPTN 035 trail. Oral Abstract 48LB. 16th Conference on Retroviruses and Opportunistic Infections February 8-11, 2009, Montreal, Canada Karim SA, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, Taha T, Kapina M, Maslankowski L, Soto-Tores L: Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PrO 2000/5 Gel for the prevention of HIV infection in women: results of the HPTN 035 trail. Oral Abstract 48LB. 16th Conference on Retroviruses and Opportunistic Infections February 8-11, 2009, Montreal, Canada
19.
go back to reference Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT: Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009, 458 (7241): 1034-8. 10.1038/nature07831.CrossRefPubMedPubMedCentral Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT: Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009, 458 (7241): 1034-8. 10.1038/nature07831.CrossRefPubMedPubMedCentral
20.
go back to reference Schlievert PM, Strandberg KL, Brosnahan AJ, Peterson ML, Pambuccian SE, Nephew KR, Brunner KG, Schultz-Darken NJ, Haase AT: Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob Agents Chemother. 2008, 52: 4448-54. 10.1128/AAC.00989-08.CrossRefPubMedPubMedCentral Schlievert PM, Strandberg KL, Brosnahan AJ, Peterson ML, Pambuccian SE, Nephew KR, Brunner KG, Schultz-Darken NJ, Haase AT: Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob Agents Chemother. 2008, 52: 4448-54. 10.1128/AAC.00989-08.CrossRefPubMedPubMedCentral
21.
go back to reference Garg S, Tambwekar KR, Vermani K, Garg A, Kaul CL, Zaneveld LJD: Compendium of Pharmaceutical Excipients for Vaginal Formulations Pharmaceutical Technology. 2001, 14-21. [http://www.pharmtech.com] Garg S, Tambwekar KR, Vermani K, Garg A, Kaul CL, Zaneveld LJD: Compendium of Pharmaceutical Excipients for Vaginal Formulations Pharmaceutical Technology. 2001, 14-21. [http://​www.​pharmtech.​com]
22.
go back to reference Zeitlin L, Whaley KJ, Hegarty TA, Moench TR, Cone RA: Tests of vaginal microbicides in the mouse genital herpes model. Contraception. 1997, 56: 329-35. 10.1016/S0010-7824(97)00154-6.CrossRefPubMed Zeitlin L, Whaley KJ, Hegarty TA, Moench TR, Cone RA: Tests of vaginal microbicides in the mouse genital herpes model. Contraception. 1997, 56: 329-35. 10.1016/S0010-7824(97)00154-6.CrossRefPubMed
23.
go back to reference Fleiss JL: Statistical Methods for Rates and Proportions. 1981, New York: John Wiley & Sons, New York, 2 Fleiss JL: Statistical Methods for Rates and Proportions. 1981, New York: John Wiley & Sons, New York, 2
24.
go back to reference Jespers V, Buve A, Van Damme L: Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men. Sex Transm Dis. 2007, 34: 519-22.PubMed Jespers V, Buve A, Van Damme L: Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men. Sex Transm Dis. 2007, 34: 519-22.PubMed
25.
go back to reference Shah S, Thasu D: Disodium edetate. Handbook of Pharmaceutical Excipients. Edited by: Rowe RC, Sheskey PJ. 2009, Quinn ME: London Pharmaceutical Press, AND Washington, DC: American Pharmacists Association, 242-244. 6 Shah S, Thasu D: Disodium edetate. Handbook of Pharmaceutical Excipients. Edited by: Rowe RC, Sheskey PJ. 2009, Quinn ME: London Pharmaceutical Press, AND Washington, DC: American Pharmacists Association, 242-244. 6
26.
go back to reference Holmstrup P, Dabelsteen E, Harder F: EDTA separation and recombination of epithelium and connective tissue of human oral mucosa. Studies of tissue transplants in nude mice. Exp Cell Biol. 1985, 53: 32-40.PubMed Holmstrup P, Dabelsteen E, Harder F: EDTA separation and recombination of epithelium and connective tissue of human oral mucosa. Studies of tissue transplants in nude mice. Exp Cell Biol. 1985, 53: 32-40.PubMed
27.
go back to reference Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, Guidos AM, Wahl RL, Hendrix CW: Hyperosmotic sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis. 2007, 195: 703-10. 10.1086/511279.CrossRefPubMed Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, Guidos AM, Wahl RL, Hendrix CW: Hyperosmotic sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis. 2007, 195: 703-10. 10.1086/511279.CrossRefPubMed
28.
go back to reference Meisel JL, Bergman D, Graney D, Saunders DR, Rubin CE: Human rectal mucosa: proctoscopic and morphological changes caused by laxatives. Gastroenterology. 1977, 72: 1274-9.PubMed Meisel JL, Bergman D, Graney D, Saunders DR, Rubin CE: Human rectal mucosa: proctoscopic and morphological changes caused by laxatives. Gastroenterology. 1977, 72: 1274-9.PubMed
29.
go back to reference Leriche M, Devroede G, Sanchez G, Rossano J: Changes in the rectal mucosa induced by hypertonic enemas. Dis Colon Rectum. 1978, 21: 227-36. 10.1007/BF02586697.CrossRefPubMed Leriche M, Devroede G, Sanchez G, Rossano J: Changes in the rectal mucosa induced by hypertonic enemas. Dis Colon Rectum. 1978, 21: 227-36. 10.1007/BF02586697.CrossRefPubMed
30.
go back to reference Khandoker M, Morshed , Sushil Jain*, Kenneth McMartin: Propylene Glycol-Mediated Cell Injury in a Primary Culture of Human Proximal Tubule Cells. 1998, 46: 410-417. Khandoker M, Morshed , Sushil Jain*, Kenneth McMartin: Propylene Glycol-Mediated Cell Injury in a Primary Culture of Human Proximal Tubule Cells. 1998, 46: 410-417.
31.
go back to reference Witcher KJ, Novick RP, Schlievert PM: Modulation of Immune Cell Proliferation by Glycerol Monolaurate. Clinical and Diagnostic Laboratory Immunology. 1996, 3: 10-13.PubMedPubMedCentral Witcher KJ, Novick RP, Schlievert PM: Modulation of Immune Cell Proliferation by Glycerol Monolaurate. Clinical and Diagnostic Laboratory Immunology. 1996, 3: 10-13.PubMedPubMedCentral
32.
go back to reference Schlievert PM, Deringer JR, Kim MH, Projan SJ, Novick RP: Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob Agents Chemother. 1992, 36: 626-631.CrossRefPubMedPubMedCentral Schlievert PM, Deringer JR, Kim MH, Projan SJ, Novick RP: Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob Agents Chemother. 1992, 36: 626-631.CrossRefPubMedPubMedCentral
33.
go back to reference Barnhart KT, Stolpen A, Pretorius ES, Malamud D: Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod. 2001, 16: 1151-4. 10.1093/humrep/16.6.1151.CrossRefPubMed Barnhart KT, Stolpen A, Pretorius ES, Malamud D: Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod. 2001, 16: 1151-4. 10.1093/humrep/16.6.1151.CrossRefPubMed
34.
go back to reference Kunz G, Beil D, Deiniger H, Einspanier A, Mall G, Leyendecker G: The uterine peristaltic pump. Normal and impeded sperm transport within the female genital tract. Adv Exp Med Biol. 1997, 424: 267-77.CrossRefPubMed Kunz G, Beil D, Deiniger H, Einspanier A, Mall G, Leyendecker G: The uterine peristaltic pump. Normal and impeded sperm transport within the female genital tract. Adv Exp Med Biol. 1997, 424: 267-77.CrossRefPubMed
35.
go back to reference Wildt L, Kissler S, Licht P, Becker W: Sperm transport in the human female genital tract and its modulation by oxytocin as assessed by hysterosalpingoscintigraphy, hysterotonography, electrohysterography and Doppler sonography. Hum Reprod Update. 1998, 4: 655-66. 10.1093/humupd/4.5.655.CrossRefPubMed Wildt L, Kissler S, Licht P, Becker W: Sperm transport in the human female genital tract and its modulation by oxytocin as assessed by hysterosalpingoscintigraphy, hysterotonography, electrohysterography and Doppler sonography. Hum Reprod Update. 1998, 4: 655-66. 10.1093/humupd/4.5.655.CrossRefPubMed
36.
go back to reference Kissler S, Siebzehnruebl E, Kohl J, Mueller A, Hamscho N, Gaetje R, Ahr A, Rody A, Kaufmann M: Uterine contractility and directed sperm transport assessed by hysterosalpingoscintigraphy (HSSG) and intrauterine pressure (IUP) measurement. Acta Obstet Gynecol Scand. 2004, 83: 369-74.CrossRefPubMed Kissler S, Siebzehnruebl E, Kohl J, Mueller A, Hamscho N, Gaetje R, Ahr A, Rody A, Kaufmann M: Uterine contractility and directed sperm transport assessed by hysterosalpingoscintigraphy (HSSG) and intrauterine pressure (IUP) measurement. Acta Obstet Gynecol Scand. 2004, 83: 369-74.CrossRefPubMed
Metadata
Title
Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse
Authors
Thomas R Moench
Russell J Mumper
Timothy E Hoen
Mianmian Sun
Richard A Cone
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-331

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine